Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE )

Documenti analoghi

• Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2–11 Years
  di: Adelaide A. Hebert, et al.
  Pubblicazione: (2025)
• Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
  di: Nirosen Vijiaratnam, et al.
  Pubblicazione: (2025)
• Twice‐Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation
  di: Syaza Ab Rahman, et al.
  Pubblicazione: (2026)
• Twice Weekly Sulfamethoxazole/Trimethoprim for Pneumocystis jiroveci Pneumonia Prophylaxis in Lung Transplant Recipients
  di: Chloe Munroe, et al.
  Pubblicazione: (2025)
• Cost‐Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom
  di: Noemi Muszbek, et al.
  Pubblicazione: (2026)